AR073909A1 - Anticuerpo aislado que se enlaza al dominio extracelular del receptor ii de tgfb humano (tgfbrii), fragmento de enlace a tgfbrii humano y composicion farmaceutica que lo comprende. - Google Patents

Anticuerpo aislado que se enlaza al dominio extracelular del receptor ii de tgfb humano (tgfbrii), fragmento de enlace a tgfbrii humano y composicion farmaceutica que lo comprende.

Info

Publication number
AR073909A1
AR073909A1 ARP090104017A ARP090104017A AR073909A1 AR 073909 A1 AR073909 A1 AR 073909A1 AR P090104017 A ARP090104017 A AR P090104017A AR P090104017 A ARP090104017 A AR P090104017A AR 073909 A1 AR073909 A1 AR 073909A1
Authority
AR
Argentina
Prior art keywords
human
tgfbrii
extracellular domain
understands
fragment
Prior art date
Application number
ARP090104017A
Other languages
English (en)
Spanish (es)
Inventor
Llc Imclone
Original Assignee
Llc Imclone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Llc Imclone filed Critical Llc Imclone
Publication of AR073909A1 publication Critical patent/AR073909A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP090104017A 2008-11-07 2009-10-19 Anticuerpo aislado que se enlaza al dominio extracelular del receptor ii de tgfb humano (tgfbrii), fragmento de enlace a tgfbrii humano y composicion farmaceutica que lo comprende. AR073909A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19869708P 2008-11-07 2008-11-07
US17036909P 2009-04-17 2009-04-17

Publications (1)

Publication Number Publication Date
AR073909A1 true AR073909A1 (es) 2010-12-09

Family

ID=41508691

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104017A AR073909A1 (es) 2008-11-07 2009-10-19 Anticuerpo aislado que se enlaza al dominio extracelular del receptor ii de tgfb humano (tgfbrii), fragmento de enlace a tgfbrii humano y composicion farmaceutica que lo comprende.

Country Status (19)

Country Link
US (2) US8147834B2 (enExample)
EP (1) EP2356152A1 (enExample)
JP (1) JP5667067B2 (enExample)
KR (1) KR101283856B1 (enExample)
CN (1) CN102209727B (enExample)
AR (1) AR073909A1 (enExample)
AU (1) AU2009311375B2 (enExample)
BR (1) BRPI0921263A2 (enExample)
CA (1) CA2742961C (enExample)
EA (1) EA025169B1 (enExample)
IL (1) IL211842A (enExample)
JO (1) JO3096B1 (enExample)
MX (1) MX2011004871A (enExample)
NZ (1) NZ591943A (enExample)
PA (1) PA8846101A1 (enExample)
SG (1) SG10201401280TA (enExample)
TW (1) TWI384998B (enExample)
WO (1) WO2010053814A1 (enExample)
ZA (1) ZA201103178B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150651B2 (en) * 2011-01-06 2015-10-06 Glaxo Group Limited Single variable domain immunoglobulins that bind TGF-beta receptor II
AR086044A1 (es) 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
PL3212225T3 (pl) 2014-10-31 2026-03-30 The Trustees Of The University Of Pennsylvania Sposoby i kompozycje zmodyfikowanych limfocytów t
AU2015380397B2 (en) 2015-01-31 2021-10-21 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
ES2951648T3 (es) 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
CN109844124B (zh) * 2016-05-20 2023-10-03 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
TW201825519A (zh) * 2016-10-18 2018-07-16 美商美國禮來大藥廠 TGFβ受體II抗體
CN110382530A (zh) * 2017-01-06 2019-10-25 供石公司 亚型特异性、背景许可性TGFβ1抑制剂及其用途
CN106884005A (zh) * 2017-01-19 2017-06-23 樊克兴 一种结直肠癌抗原特异性t细胞的制备方法
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
EP3700568A4 (en) 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
WO2019084053A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
CN107973853B (zh) * 2017-12-12 2021-04-30 山西农业大学 一种利用特征多肽制备Smad2蛋白特异性抗体的方法及其应用
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN116199780A (zh) * 2019-12-24 2023-06-02 美勒斯公司 TGF-β-RII结合蛋白质
KR102314157B1 (ko) * 2020-01-10 2021-10-19 주식회사 뉴클릭스바이오 TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법
WO2022099090A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. Heterodimeric antibodies that bind tgfbrii
KR20240046905A (ko) * 2021-08-20 2024-04-11 아케소 바이오파마, 인크. 항-TIGIT 항체 및 TGF-βR을 포함하는 융합 단백질, 이의 약학 조성물, 및 용도
JP2025512025A (ja) * 2022-04-15 2025-04-16 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 抗ｃｄ４０抗体及びその使用
CN116178567B (zh) * 2022-10-28 2025-01-28 四川大学华西医院 一种靶向TGFβRII的嵌合抗原受体及其用途
WO2026030756A2 (en) * 2024-08-02 2026-02-05 Salspera, Llc Liver disease treatments using attenuated strains of salmonella typhimurium

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
AU671606B2 (en) 1991-10-31 1996-09-05 Whitehead Institute For Biomedical Research TGF-beta type receptor cDNAs and uses therefor
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
JP2004121001A (ja) * 2002-08-07 2004-04-22 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対する高親和性モノクローナル抗体
EP1992360A4 (en) 2006-02-01 2010-02-17 Univ Tokyo COMMON USE OF A TGF BETA SIGNAL HEMMER AND AN ANTITUMORAL AGENT

Also Published As

Publication number Publication date
EA025169B1 (ru) 2016-11-30
PA8846101A1 (es) 2010-06-28
AU2009311375B2 (en) 2014-07-31
CN102209727A (zh) 2011-10-05
TW201026326A (en) 2010-07-16
JP2012508170A (ja) 2012-04-05
TWI384998B (zh) 2013-02-11
KR20110067155A (ko) 2011-06-21
EP2356152A1 (en) 2011-08-17
AU2009311375A1 (en) 2010-05-14
IL211842A0 (en) 2011-06-30
US8147834B2 (en) 2012-04-03
CA2742961C (en) 2016-08-30
IL211842A (en) 2016-09-29
JO3096B1 (ar) 2017-03-15
ZA201103178B (en) 2012-10-31
MX2011004871A (es) 2011-07-13
CN102209727B (zh) 2014-07-30
CA2742961A1 (en) 2010-05-14
EA201170659A1 (ru) 2011-10-31
NZ591943A (en) 2012-11-30
JP5667067B2 (ja) 2015-02-12
BRPI0921263A2 (pt) 2015-08-04
WO2010053814A1 (en) 2010-05-14
KR101283856B1 (ko) 2013-07-15
US20100119516A1 (en) 2010-05-13
US20120177666A1 (en) 2012-07-12
SG10201401280TA (en) 2014-05-29

Similar Documents

Publication Publication Date Title
PA8846101A1 (es) Anticuerpos del receptor ii anti-tgf-beta
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
AR119754A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
PH12018501419B1 (en) Pharmaceutical composition comprising bispecific antibody constructs
AR079333A1 (es) Anticuerpos contra csf -1r humano y usos de los mimos
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
AR074756A1 (es) Anticuerpos contra la angiopoyetina-2 humana
NO20081883L (no) Modulasjon av glukokortikoidreseptorekspresjon
BR112012005970A2 (pt) moduladores tricíclicos de proteína quinase
CR11005A (es) Formulaciones estables de anticuerpos
CL2016003014A1 (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi) (divisional sol. n°230-11).
BRPI0906404B8 (pt) construção de fusão com domínio lítico, seus usos, composição farmacêutica, bem como processo para reduzir ou inibir seletivamente a proliferação de uma célula que expressa um receptor, ligante ou antígeno
EA200900403A1 (ru) Соединения, которые модулируют рецептор св2
CL2012000508A1 (es) Composicion para la aplicacion en cultivos agricolas al aire libre o invernaderos que comprende zeolita, y aditivos; uso de la composicion para aumentar el rendimiento de los cultivos agricolas.
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
EA201001639A1 (ru) Композиции и способы их получения и применения
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
EA201200019A1 (ru) Соединения, которые селективно модулируют рецептор св2
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
TN2010000169A1 (en) Molecules and methods for modulating complement component
MX2011007101A (es) Composiciones de hidrolizados proteicos que tienen capacidad mejorada para liberar colecistocinina (cck).
EA201100523A1 (ru) Соединения сульфонила, которые селективно модулируют рецептор св2

Legal Events

Date Code Title Description
FB Suspension of granting procedure